CSL (ASX:CSL) has agreed to acquire from uniQure exclusive global license rights to commercialise an adeno-associated virus gene therapy program, for the treatment of haemophilia B.
The AMT-061 program, currently in Phase 3 clinical trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with haemophilia B.
The agreement with uniQure will see it receive a $US450 million upfront payment from CSL, followed by regulatory and commercial sales milestone payments and royalties.
Shares in CSL (ASX:CSL) are trading 0.4 per cent higher at $293.55.
